Blurbs

Analysts Offer Insights on Healthcare Companies: Akebia Therapeutics (AKBA) and TFF Pharmaceuticals (TFFP)

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Akebia Therapeutics (AKBAResearch Report) and TFF Pharmaceuticals (TFFPResearch Report).

Akebia Therapeutics (AKBA)

Needham analyst Serge Belanger downgraded Akebia Therapeutics to Hold today. The company’s shares closed last Wednesday at $0.83, close to its 52-week low of $0.67.

According to TipRanks.com, Belanger is a 4-star analyst with an average return of 9.0% and a 48.3% success rate. Belanger covers the Healthcare sector, focusing on stocks such as Clarus Therapeutics Holdings, Amphastar Pharmaceuticals, and Collegium Pharmaceutical.

Akebia Therapeutics has an analyst consensus of Hold, with a price target consensus of $3.00, a 28.5% upside from current levels. In a report released yesterday, Piper Sandler also downgraded the stock to Hold with a $2.00 price target.

See today’s best-performing stocks on TipRanks >>

TFF Pharmaceuticals (TFFP)

In a report released yesterday, Michael Okunewitch from Maxim Group maintained a Buy rating on TFF Pharmaceuticals, with a price target of $14.00. The company’s shares closed last Wednesday at $6.43, close to its 52-week low of $5.09.

According to TipRanks.com, Okunewitch is a 1-star analyst with an average return of -7.3% and a 50.0% success rate. Okunewitch covers the Healthcare sector, focusing on stocks such as Citius Pharmaceuticals, Kiora Pharmaceuticals, and HCW Biologics.

TFF Pharmaceuticals has an analyst consensus of Moderate Buy, with a price target consensus of $16.00, a 149.2% upside from current levels. In a report issued on March 29, B.Riley Financial also maintained a Buy rating on the stock with a $18.00 price target.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Read More on AKBA:

Tired of arriving late to the Big Returns Party?​
Most investors don’t have major gainers like TSLA or NVDA on their radar from the start.
The profusion of opinions on social media and financial blogs makes it impossible to distinguish between real growth potential and pure hype.
​​For the past decade, we have developed and perfected technology designed to help private investors, just like you, find the best opportunities, with the greatest upside potential, in any financial climate.​
Learn More
Videos
Videos

Latest News Feed